Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AMGN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab… NCT07222553 · Immunoglobulin G4-related Disease Inebilizumab | AMGN Amgen | Phase 2 | Recruiting was not yet recruiting | 15 | Jun 10, 2031 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis NCT06072482 · Antineutrophil Cytoplasmic Antibody-associated Vasculitis Avacopan, Placebo | AMGN Amgen | Phase 4 | Recruiting | 300 | Dec 31, 2036 | Registry ↗ |
| Nov 13, 2026 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Com… NCT05920356 · Non-Small Cell Lung Cancer (NSCLC) Sotorasib, Pembrolizumab | AMGN Amgen | Phase 3 | Recruiting | 750 | Jun 30, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibe… NCT07614776 · Neovascular Age-related Macular Degeneration, nAMD ABP 938 8 mg, Aflibercept (US) 8 mg | AMGN Amgen | Phase 3 | Recruiting | 304 | Jul 31, 2027 | Registry ↗ |
| Nov 12, 2026 | Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen… NCT07140900 · Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Xaluritamig, Darolutamide | AMGN Amgen | Phase 1 | Active, not recruiting was recruiting | 60 | Oct 27, 2027 | Registry ↗ |
| Nov 12, 2026 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer NCT04221542 · Prostate Cancer AMG 509, Abiraterone | AMGN Amgen | Phase 1 | Recruiting | 505 | Jul 28, 2030 | Registry ↗ |
| Nov 10, 2026 | A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers NCT07745907 · Healthy Participants AMG 691 | AMGN Amgen | Phase 1 | Active, not recruiting was recruiting | 28 | Mar 17, 2027 | Registry ↗ |
| Nov 10, 2026 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC NCT03792841 · Metastatic Castration-resistant Prostate Cancer, Prostate C… acapatamab, Pembrolizumab | AMGN Amgen | Phase 1 | Terminated | 212 | Jun 29, 2023 | Registry ↗ |
| Nov 9, 2026 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity… NCT07871409 · Obesity, Overweight Maridebart cafraglutide, Autoinjector | AMGN Amgen | Phase 3 | Recruiting was not yet recruiting | 230 | Jun 16, 2027 | Registry ↗ |
| Nov 9, 2026 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction NCT05284747 · Cardiovascular Disease, Myocardial Infarction Evolocumab, Routine Lipid Management | AMGN Amgen | Phase 4 | Active, not recruiting | 6,019 | May 29, 2027 | Registry ↗ |
| Nov 6, 2026 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When… NCT07921316 · Obesity, Overweight Maridebart cafraglutide | AMGN Amgen | Phase 1 | Not yet recruiting | 356 | Jul 26, 2027 | Registry ↗ |
| Nov 6, 2026 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-… NCT07575399 · Obesity or Overweight Maridebart Cafraglutide | AMGN Amgen | Phase 3 | Recruiting | 300 | Jan 3, 2028 | Registry ↗ |
| Nov 6, 2026 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Sma… NCT06211036 · Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Can… Tarlatamab, Durvalumab | AMGN Amgen | Phase 3 | Active, not recruiting | 563 | Apr 2, 2030 | Registry ↗ |
| Nov 5, 2026 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes NCT07866066 · Diabetes Mellitus, Type 2 Maridebart cafraglutide, Semaglutide | AMGN Amgen | Phase 3 | Recruiting was not yet recruiting | 1,300 | Sep 6, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Pso… NCT05767047 · Behçet's Disease, Juvenile Psoriatic Arthritis Apremilast | AMGN Amgen | Phase 3 | Recruiting | 48 | Mar 17, 2036 | Registry ↗ |
| Nov 4, 2026 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small… NCT03319940 · Small Cell Lung Carcinoma Tarlatamab, Pembrolizumab | AMGN Amgen | Phase 1 | Active, not recruiting | 269 | Dec 31, 2027 | Registry ↗ |
| Nov 3, 2026 | A Trial of Inebilizumab in Participants With Autoimmune Hepatitis NCT07598825 · Autoimmune Hepatitis, AIH Inebilizumab, Placebo | AMGN Amgen | Phase 3 | Recruiting | 180 | Jul 30, 2031 | Registry ↗ |
| Nov 2, 2026 | Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an E… NCT07908641 · Psoriasis, Arthritis, Psoriatic Apremilast XR, Apremilast IR | AMGN Amgen | Phase 1 | Not yet recruiting | 114 | Jan 10, 2027 | Registry ↗ |
| Nov 2, 2026 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants… NCT07908316 · Obesity, Overweight Maridebart cafraglutide | AMGN Amgen | Phase 1 | Recruiting | 180 | Dec 20, 2027 | Registry ↗ |
| Nov 2, 2026 | Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B P… NCT06054113 · B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refracto… Blinatumomab | AMGN Amgen | Phase 2 | Active, not recruiting | 18 | Jan 6, 2026 | Registry ↗ |
| Oct 30, 2026 | A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Partici… NCT06637371 · Asthma AMG 691, Placebo | AMGN Amgen | Phase 1 | Active, not recruiting | 21 | Apr 10, 2027 | Registry ↗ |
| Oct 29, 2026 | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sar… NCT07297979 · Ewing Sarcoma Xaluritamig | AMGN Amgen | Phase 1 | Recruiting | 50 | May 26, 2030 | Registry ↗ |
| Oct 29, 2026 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obe… NCT07037459 · Heart Failure With Preserved Ejection Fraction, Heart Failu… Maridebart cafraglutide, Placebo | AMGN Amgen | Phase 3 | Recruiting | 5,056 | Jun 30, 2028 | Registry ↗ |
| Oct 29, 2026 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With At… NCT07037433 · Atherosclerotic Cardiovascular Disease, Overweight Maridebart Cafraglutide, Placebo | AMGN Amgen | Phase 3 | Active, not recruiting was recruiting | 12,800 | Jun 30, 2028 | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome… NCT06104124 · Sjogren's Syndrome Dazodalibep, Placebo | AMGN Amgen | Phase 3 | Completed | 651 | Jul 23, 2026 | Registry ↗ |
| Oct 29, 2026 | Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to… NCT05909761 · Neuromyelitis Optica Spectrum Disorder, Pregnancy Related UPLIZNA | AMGN Amgen | — | Recruiting | 60 | Oct 31, 2032 | Registry ↗ |
| Oct 28, 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants… NCT05481411 · Hepatic Impairment Olpasiran | AMGN Amgen | Phase 1 | Completed | 25 | Apr 5, 2023 | Registry ↗ |
| Oct 28, 2026 | Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine NCT03832998 · Migraine Erenumab Dose 1, Erenumab Dose 2 | AMGN Amgen | Phase 3 | Completed | 284 | Jan 8, 2025 | Registry ↗ |
| Oct 27, 2026 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial NCT05581303 · Atherosclerotic Cardiovascular Disease Placebo, Olpasiran | AMGN Amgen | Phase 3 | Active, not recruiting | 7,297 | Mar 31, 2028 | Registry ↗ |
| Oct 23, 2026 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab… NCT06987539 · Generalized Myasthenia Gravis Inebilizumab | AMGN Amgen | Phase 2 | Recruiting | 15 | Mar 13, 2030 | Registry ↗ |
| Oct 23, 2026 | A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants NCT06411860 · Basic Science Placebo, Olpasiran | AMGN Amgen | Phase 1 | Completed | 32 | Nov 29, 2024 | Registry ↗ |
| Oct 23, 2026 | A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy P… NCT06268860 · Atopic Dermatitis Rocatinlimab vial injection, Rocatinlimab prefilled syringe | AMGN Amgen | Phase 1 | Completed | 240 | Aug 30, 2024 | Registry ↗ |
| Oct 23, 2026 | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis NCT06088199 · Plaque Psoriasis Apremilast | AMGN Amgen | Phase 3 | Completed | 51 | Aug 12, 2026 | Registry ↗ |
| Oct 23, 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants… NCT05489614 · Renal Impairment Olpasiran | AMGN Amgen | Phase 1 | Completed | 33 | Oct 24, 2023 | Registry ↗ |
| Oct 23, 2026 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Recepto… NCT05052801 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Bemarituzumab, mFOLFOX6 | AMGN Amgen | Phase 3 | Completed | 547 | Jun 20, 2025 | Registry ↗ |
| Oct 23, 2026 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors NCT04362748 · Advanced Solid Tumors AMG 256 | AMGN Amgen | Phase 1 | Completed | 34 | Sep 21, 2023 | Registry ↗ |
| Oct 23, 2026 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointesti… NCT03362177 · Chemotherapy-induced Thrombocytopenia Romiplostim, Placebo | AMGN Amgen | Phase 3 | Completed | 165 | Jan 25, 2024 | Registry ↗ |
| Oct 21, 2026 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two… NCT06502977 · Extensive Stage Small Cell Lung Cancer Tarlatamab | AMGN Amgen | Phase 2 | Active, not recruiting | 32 | Mar 28, 2025 | Registry ↗ |
| Oct 21, 2026 | A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk… NCT06079476 · Postmenopausal Osteoporosis Romosozumab | AMGN Amgen | Phase 4 | Completed | 100 | Oct 18, 2025 | Registry ↗ |
| Oct 20, 2026 | AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors NCT07403721 · Metastatic or Locally Advanced Solid Tumors With Microsatel… AMG 436 | AMGN Amgen | Phase 1 | Recruiting | 464 | Jan 1, 2030 | Registry ↗ |
| Oct 20, 2026 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemother… NCT07213674 · Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate | AMGN Amgen | Phase 3 | Recruiting | 750 | Jan 7, 2030 | Registry ↗ |
| Oct 20, 2026 | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis NCT04804553 · Active Juvenile Psoriatic Arthritis Apremilast, Placebo | AMGN Amgen | Phase 3 | Recruiting | 60 | Mar 21, 2028 | Registry ↗ |
| Oct 19, 2026 | A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokineti… NCT07388498 · Uncontrolled Gout Pegloticase, Methotrexate | AMGN Amgen | Phase 3 | Recruiting | 270 | Jun 18, 2028 | Registry ↗ |
| Oct 19, 2026 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advance… NCT05800964 · Advanced Solid Tumors AMG 305 | AMGN Amgen | Phase 1 | Terminated | 37 | Jan 22, 2026 | Registry ↗ |
| Oct 19, 2026 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cel… NCT03937154 · Chemotherapy-induced Thrombocytopenia Romiplostim, Placebo | AMGN Amgen | Phase 3 | Active, not recruiting | 145 | Mar 10, 2026 | Registry ↗ |
| Oct 14, 2026 | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine NCT03836040 · Migraine Erenumab Dose 1, Erenumab Dose 2 | AMGN Amgen | Phase 3 | Active, not recruiting | 457 | Nov 19, 2025 | Registry ↗ |
| Oct 13, 2026 | Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered… NCT07811999 · Healthy Participants Romosozumab | AMGN Amgen | Phase 1 | Recruiting | 308 | Jan 14, 2027 | Registry ↗ |
| Oct 13, 2026 | A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living W… NCT07310563 · Overweight, Obesity AMG 133, Ondansetron | AMGN Amgen | Phase 1 | Completed | 59 | May 9, 2025 | Registry ↗ |
| Oct 6, 2026 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positi… NCT07225686 · Obesity, Obstructive Sleep Apnea Maridebart cafraglutide, Placebo | AMGN Amgen | Phase 3 | Active, not recruiting | 250 | Aug 20, 2027 | Registry ↗ |
| Oct 6, 2026 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With… NCT06745323 · Small Cell Lung Cancer (SCLC) Tarlatamab | AMGN Amgen | Phase 2 | Active, not recruiting | 252 | Aug 10, 2029 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances